Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00076206|
Recruitment Status : Terminated
First Posted : January 19, 2004
Last Update Posted : December 9, 2015
|Condition or disease||Intervention/treatment||Phase|
|Rheumatoid Arthritis||Drug: CCI-779 Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Oral Dose Levels (1, 2, And 4 Mg) of CCI-779 in Subjects With Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy|
|Study Start Date :||December 2003|
|Actual Primary Completion Date :||August 2005|
|Actual Study Completion Date :||August 2005|
CCI-779 1 mg dose to be taken orally daily up to 12 weeks.
CCI-779 2 mg dose to be taken orally daily up to 12 weeks.
CCI-779 4 mg dose to be taken orally daily up to 12 weeks.
Placebo Comparator: D
Placebo dose to be taken orally daily up to 12 weeks.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00076206
|Study Director:||Medical Monitor, MD||Wyeth is now a wholly owned subsidiary of Pfizer|